Vimian^m

Together, we improve animal health through science and technology for better lives

Q3 presentation November 2023

Q3 highlights

/ Strong organic growth ahead of the industry

/ Improved cash flow from operating activities


/ Significantly higher net profit

Adjusted EBITA margin primarily reflects sales pattern in MedTech and mix effect from strong growth US Specialised Nutrition in Specialty Pharma





Continued strong organic growth of 12% in the third quarter




Revenue development

- / Q3 strong organic growth of 12%
- / Specialty Pharma 18%, Veterinary Services 14%
- / YTD organic growth 13%, ahead of the animal health industry
- / Q3 contribution from acquisitions 7%
- / One small bolt-on acquisition closed in Q3
- / Q3 negative impact of 6% from currency movements

Margin reflects sales pattern in MedTech, mix and investments in Specialty Pharma

Year over year development of adjusted EBITA margin



/ Gross margin 67.5% (68.7%)


/ Excluding mix impact from GlobalOne, gross margin is stable at ~72%

/ Adjusted EBITA margin 22.9% reflects sales pattern in MedTech as well as mix and investments in Specialty Pharma

/ We remain committed to margin expansion and continue our efforts in the coming quarters

Page 4

Strong global footprint, 43% of LTM revenue from North America





Strong track record since 2016

Global niches with unmet medical needs, untapped white space

Growth driven both by organic initiatives and continuous M&A

/ Multiple organic growth initiatives underway and synergy potential






Adjusted EBITA

333

281

173



Specialty Pharma

Strong organic growth 18%, double-digit growth in Specialty Pharmaceuticals, Specialised Nutrition and Dermatology

Double-digit growth in Allergy Test & Treatments in Europe

/ High commercial activity with 15 congresses of which two as main sponsor


/ Initiating further efficiencies across European operations

18% Organic growth

12% Adj. EBITA growth

-2.1pp Adj. EBITA margin

Revenue and Adj. EBITA



Mix impact from strong growth in US Specialised Nutrition (70% of decline), lower margin in US allergy (lower sales & investment in new test launch) and strategic investments in the business, including R&D and sales force

Page 7



MedTech

Slow growth reflects sales pattern in the US with extended AOP and small buildup of backorders

High single-digit growth in Europe and APAC

/ 13% organic growth YTD reflects positive underlying momentum

Continued efforts to optimise supply chain and right-size inventory levels




4%

Organic growth

-18%

Adj. EBITA decline



Page 8



Veterinary Services

Strong organic growth with positive momentum in key geographies

High recruitment pace with 620 new members and good conversion to higher membership tiers

Digital expertise leveraged across the Group for shared CRM and data warehouse


60% Adj. EBITA growth

14%

Organic growth

+5.2pp Adj. EBITA margin

Revenue and Adj. EBITA





Diagnostics

Solid organic growth of 9%, well ahead of the livestock market

Cost program finalised. Robust margin compared to livestock peers

Progressing innovations targeting companion animal diagnostics, ramping up investments over the next year


9% Organic growth

85% Adj. EBITA growth

+8.5pp Adj. EBITA margin

Page 10

Revenue and Adj. EBITA



Quarterly ESG highlights

/ Established carbon reduction plan for Scope 1&2 - in line with Science Based Targets and Paris Agreement

/ Process ongoing to uncover Scope 3 emissions

/ New Chief of People onboard per 1st November – focus on leadership and overall employee experience

	People	Animals	Planet
Ambition	Create the best place to work	Leading innovator of solutions that improve welfare and reduce AMR	Clear path to transitior towards net-zero
		3 martin	
Focus areas	1. Health and wellbeing 2. Training and education 3. Diversity and inclusion 4. Business ethics	5. Animal welfare 6. Antimicrobial resist- ance (AMR)	7. Climate impact 8. Responsible supply chain

Third Quarter Financials

EUR m	Q3 2022 July – September	Q3 2023 July – September	YTD 2022 January – September	YTD 2023 January – September
Adjusted EBITA	17.2	18.3	55.4	64.7
Adjusted EBITA margin (%)	24.3%	22.9%	26.9%	26.0%
Non-recurring items	-3.6	-2.6	-14.1	-9.6
PPA related amortisation	-4.8	-5.8	-13.5	-16.5
Operating profit (EBIT)	8.8	9.9	27.9	38.6
EBIT margin (%)	12.5%	12.4%	13.6%	15.5%
Net financial items	-9.4	-0.1	-8.5	-11.8
Profit before tax	-0.6	9.8	19.4	25.8
Тах	-1.0	-2.2	-5.5	-9.5
Profit for the period	-1.6	7.6	13.8	16.3

Q3 Income Statement below EBIT


/ Q3 EBIT +12% to EUR 9.9m (8.8), margin 12.4%

/ Lower amount of non-recurring items EUR -2.6m (-3.6)

• Primarily M&A in Specialty Pharma and legal costs in MedTech

/ Net financial items of EUR -0.1m (-9.4)

- Financing costs EUR -5.1m interest rate 6.3%
- Contingent considerations EUR -0.4m quarterly discounting impact offset by positive impact from probability adjustments
- Positive FX impact EUR 5.4m
- / Tax EUR -2.2m



Net Debt and Leverage

/ Net debt per 30 September 2023 EUR 287.9m

/ Cash and cash equivalents EUR 49.3m

/ Net Debt / LTM Pro-forma EBITDA 3.0x at target level

/ Net debt not impacted by settlement payment in US patent dispute – payment USD 70m Q223. Receivable on balance sheet re-classified as a "non-current" receivable


Current trading and update

/ High single digit growth in October – acceleration of sales in MedTech as pull-forward effect abates

/ Continued efforts to deliver margin expansion

/ Mix effect from strong growth in US Specialised Nutrition and effect of investments prevail for the remainder of 2023

/ Legal process to retrieve compensation for US litigation is ongoing




Eye on patient, mind on innovation

Nextmune deep-dive




NOVEMBER 8, 2023

Transformation since IPO



Our business in a nutshell (1 / 2)





Our business in a nutshell (2 / 2)

Ň



	Allergy	Specialty Pharmaceut	Dermatology	Specialized Nutrition	
Characteristics	Tailored name-patient pharmaceuticals and diagnostics for veterinary channel		Pharmaceuticals and OTC for veterinary, pet specialty retail, retail and online		
Description	Diagnostics and treatments to treat root-cause of allergy	Specialty medicine with innovative formulas	Topical solutions to treat infections and protect the skin	Specialized nutrition for specific conditions and general health	
Category	Dx, Rx (veterinary)	Rx (veterinary)	Rx, Rx OTC (veterinary), OTC (B2C, retail)	Rx, Rx OTC (veterinary), OTC (B2C, retail)	
Offering	>30 SKUs	> 500 core SKUs	>130 SKUs	>300 SKUs	
Operations	>90% own production	>100% own production	>60% own production	Fully outsourced	
Brands	PAX Artuvetrin®	BOVA		GLOBALONE® Nutrition and Quality for Life.	
Go to market		12 markets with	own sales force	🕂 🕀 🤀 🗐 🖨	

Four-pronged growth strategy











Capture significant white space Drive innovation and product development Ensure full product availability in all geographies and channels

Unlock best practices and efficiencies

What is our potential?

Cuit

'White space', product innovation and geographic expansion

Allergy

Specialty Pharmaceuticals

of all US scripts are for specialty

Short time-to-market for

innovative and high-quality

10%

 \checkmark

 \checkmark

pharmaceuticals

medicine

Dermatology

1-in-5

clinic visits related to dermatological issues

- Shift-away from antibiotics to Rx \checkmark OTC
- Regulations allow for swift time \checkmark to market
- Strong brand equity and EU \checkmark footprint

Direct go-to-market in EU big-5, access new channels



Specialized Nutrition

EUR 2 bn addressable market in North

America and EU

- Increased focus on preventive \checkmark care
- \checkmark Multi-channel market opportunities
- Niche market leadership \checkmark

New products, account and channel expansion in existing markets



1-in-6 dogs suffers from allergy, the most common chronic illness

Underdiagnosed and \checkmark undertreated condition

- \checkmark Test-and-treat market model creating lock-in-effect -> recurring revenue
- Leading global player in allergy \checkmark

Innovative R&D pipeline, exploit 'white space'



High-margin business, particularly in batching Market leader in the UK, EU and \checkmark AUS

New innovations, further build and penetrate existing markets



21

A strong platform for profitable, cash-generative growth



Doubled in size since IPO, healthy momentum



Attractive industry with structural growth

>6% CAGR 2005-2020 in the US

Multi-pronged growth strategy

>15% organic growth YTD

Operational leverage from robust infrastructure in place

12

direct go-to-market country organizations, efficient corporate functions

January-September highlights

/ Strong organic growth ahead of the industry

/ Net profit up 18% vs previous year

/ Adj EBITA margin less impacted by sales pattern in MedTech

/ Cash flow from operating activities EUR 19.9m*. Positive net cash flow EUR 6m

/ Net debt reduced by EUR 8.2m, leverage at target level 3.0x





Q&A

